Association of FKBP5 polymorphisms with suicidal events in the treatment of resistant depression in adolescents (TORDIA) study

David Brent, Nadine Melhem, Robert Ferrell, Graham Emslie, Karen Dineen Wagner, Neal Ryan, Benedetto Vitiello, Boris Birmaher, Taryn Mayes, Jamie Zelazny, Matthew Onorato, Bernie Devlin, Greg Clarke, Lynn DeBar, Marty Keller

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Objective: The authors sought to assess the relationship between candidate genes and two clinical outcomes, namely, symptomatic improvement and the occurrence of suicidal events, in a sample of treatment-resistant depressed adolescents. Method: A subsample of depressed adolescents participating in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) trial, 155 of whom were of European origin, were genotyped with respect to 21 polymorphisms on 12 genes that have a reported association with depression, treatment response, or suicidal events. Participants had not responded to a previous adequate trial with an antidepressant and were randomized to receive either another selective serotonin reuptake inhibitor or venlafaxine, with or without cognitive-behavioral therapy (CBT). Single-nucleotide polymorphism (SNP) analyses were conducted using PLINK with permutation procedures. Results: No relationship was observed between any polymorphism and response to treatment. The FKBP5 (which codes for a protein causing subsensitivity of the glucocorticoid receptor) rs1360780TT and rs3800373GG genotypes were associated with suicidal events (N=18), even after controlling for treatment effects and relevant covariates. These two SNPs were in significant linkage disequilibrium (r=0.91). Conclusions: The FKBP5 genotypes associated with suicidal events in this study have been reported by others to cause the greatest degree of glucocorticoid receptor subsensitivity. These results are consistent with those of other studies linking alterations in the hypothalamic-pituitary-adrenal axis with suicidal behavior. The small number of events and lack of a placebo condition make these results preliminary. Replication with a larger sample and a placebo condition is needed to assess whether these events are related to treatment.

Original languageEnglish (US)
Pages (from-to)190-197
Number of pages8
JournalAmerican Journal of Psychiatry
Volume167
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Treatment-Resistant Depressive Disorder
Glucocorticoid Receptors
Single Nucleotide Polymorphism
Genotype
Placebos
Therapeutics
Linkage Disequilibrium
Serotonin Uptake Inhibitors
Cognitive Therapy
Antidepressive Agents
Genes
Depression
Proteins

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Association of FKBP5 polymorphisms with suicidal events in the treatment of resistant depression in adolescents (TORDIA) study. / Brent, David; Melhem, Nadine; Ferrell, Robert; Emslie, Graham; Wagner, Karen Dineen; Ryan, Neal; Vitiello, Benedetto; Birmaher, Boris; Mayes, Taryn; Zelazny, Jamie; Onorato, Matthew; Devlin, Bernie; Clarke, Greg; DeBar, Lynn; Keller, Marty.

In: American Journal of Psychiatry, Vol. 167, No. 2, 02.2010, p. 190-197.

Research output: Contribution to journalArticle

Brent, D, Melhem, N, Ferrell, R, Emslie, G, Wagner, KD, Ryan, N, Vitiello, B, Birmaher, B, Mayes, T, Zelazny, J, Onorato, M, Devlin, B, Clarke, G, DeBar, L & Keller, M 2010, 'Association of FKBP5 polymorphisms with suicidal events in the treatment of resistant depression in adolescents (TORDIA) study', American Journal of Psychiatry, vol. 167, no. 2, pp. 190-197. https://doi.org/10.1176/appi.ajp.2009.09040576
Brent, David ; Melhem, Nadine ; Ferrell, Robert ; Emslie, Graham ; Wagner, Karen Dineen ; Ryan, Neal ; Vitiello, Benedetto ; Birmaher, Boris ; Mayes, Taryn ; Zelazny, Jamie ; Onorato, Matthew ; Devlin, Bernie ; Clarke, Greg ; DeBar, Lynn ; Keller, Marty. / Association of FKBP5 polymorphisms with suicidal events in the treatment of resistant depression in adolescents (TORDIA) study. In: American Journal of Psychiatry. 2010 ; Vol. 167, No. 2. pp. 190-197.
@article{ff5dd75e02d4414187085cec86fc9e35,
title = "Association of FKBP5 polymorphisms with suicidal events in the treatment of resistant depression in adolescents (TORDIA) study",
abstract = "Objective: The authors sought to assess the relationship between candidate genes and two clinical outcomes, namely, symptomatic improvement and the occurrence of suicidal events, in a sample of treatment-resistant depressed adolescents. Method: A subsample of depressed adolescents participating in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) trial, 155 of whom were of European origin, were genotyped with respect to 21 polymorphisms on 12 genes that have a reported association with depression, treatment response, or suicidal events. Participants had not responded to a previous adequate trial with an antidepressant and were randomized to receive either another selective serotonin reuptake inhibitor or venlafaxine, with or without cognitive-behavioral therapy (CBT). Single-nucleotide polymorphism (SNP) analyses were conducted using PLINK with permutation procedures. Results: No relationship was observed between any polymorphism and response to treatment. The FKBP5 (which codes for a protein causing subsensitivity of the glucocorticoid receptor) rs1360780TT and rs3800373GG genotypes were associated with suicidal events (N=18), even after controlling for treatment effects and relevant covariates. These two SNPs were in significant linkage disequilibrium (r=0.91). Conclusions: The FKBP5 genotypes associated with suicidal events in this study have been reported by others to cause the greatest degree of glucocorticoid receptor subsensitivity. These results are consistent with those of other studies linking alterations in the hypothalamic-pituitary-adrenal axis with suicidal behavior. The small number of events and lack of a placebo condition make these results preliminary. Replication with a larger sample and a placebo condition is needed to assess whether these events are related to treatment.",
author = "David Brent and Nadine Melhem and Robert Ferrell and Graham Emslie and Wagner, {Karen Dineen} and Neal Ryan and Benedetto Vitiello and Boris Birmaher and Taryn Mayes and Jamie Zelazny and Matthew Onorato and Bernie Devlin and Greg Clarke and Lynn DeBar and Marty Keller",
year = "2010",
month = "2",
doi = "10.1176/appi.ajp.2009.09040576",
language = "English (US)",
volume = "167",
pages = "190--197",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "2",

}

TY - JOUR

T1 - Association of FKBP5 polymorphisms with suicidal events in the treatment of resistant depression in adolescents (TORDIA) study

AU - Brent, David

AU - Melhem, Nadine

AU - Ferrell, Robert

AU - Emslie, Graham

AU - Wagner, Karen Dineen

AU - Ryan, Neal

AU - Vitiello, Benedetto

AU - Birmaher, Boris

AU - Mayes, Taryn

AU - Zelazny, Jamie

AU - Onorato, Matthew

AU - Devlin, Bernie

AU - Clarke, Greg

AU - DeBar, Lynn

AU - Keller, Marty

PY - 2010/2

Y1 - 2010/2

N2 - Objective: The authors sought to assess the relationship between candidate genes and two clinical outcomes, namely, symptomatic improvement and the occurrence of suicidal events, in a sample of treatment-resistant depressed adolescents. Method: A subsample of depressed adolescents participating in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) trial, 155 of whom were of European origin, were genotyped with respect to 21 polymorphisms on 12 genes that have a reported association with depression, treatment response, or suicidal events. Participants had not responded to a previous adequate trial with an antidepressant and were randomized to receive either another selective serotonin reuptake inhibitor or venlafaxine, with or without cognitive-behavioral therapy (CBT). Single-nucleotide polymorphism (SNP) analyses were conducted using PLINK with permutation procedures. Results: No relationship was observed between any polymorphism and response to treatment. The FKBP5 (which codes for a protein causing subsensitivity of the glucocorticoid receptor) rs1360780TT and rs3800373GG genotypes were associated with suicidal events (N=18), even after controlling for treatment effects and relevant covariates. These two SNPs were in significant linkage disequilibrium (r=0.91). Conclusions: The FKBP5 genotypes associated with suicidal events in this study have been reported by others to cause the greatest degree of glucocorticoid receptor subsensitivity. These results are consistent with those of other studies linking alterations in the hypothalamic-pituitary-adrenal axis with suicidal behavior. The small number of events and lack of a placebo condition make these results preliminary. Replication with a larger sample and a placebo condition is needed to assess whether these events are related to treatment.

AB - Objective: The authors sought to assess the relationship between candidate genes and two clinical outcomes, namely, symptomatic improvement and the occurrence of suicidal events, in a sample of treatment-resistant depressed adolescents. Method: A subsample of depressed adolescents participating in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) trial, 155 of whom were of European origin, were genotyped with respect to 21 polymorphisms on 12 genes that have a reported association with depression, treatment response, or suicidal events. Participants had not responded to a previous adequate trial with an antidepressant and were randomized to receive either another selective serotonin reuptake inhibitor or venlafaxine, with or without cognitive-behavioral therapy (CBT). Single-nucleotide polymorphism (SNP) analyses were conducted using PLINK with permutation procedures. Results: No relationship was observed between any polymorphism and response to treatment. The FKBP5 (which codes for a protein causing subsensitivity of the glucocorticoid receptor) rs1360780TT and rs3800373GG genotypes were associated with suicidal events (N=18), even after controlling for treatment effects and relevant covariates. These two SNPs were in significant linkage disequilibrium (r=0.91). Conclusions: The FKBP5 genotypes associated with suicidal events in this study have been reported by others to cause the greatest degree of glucocorticoid receptor subsensitivity. These results are consistent with those of other studies linking alterations in the hypothalamic-pituitary-adrenal axis with suicidal behavior. The small number of events and lack of a placebo condition make these results preliminary. Replication with a larger sample and a placebo condition is needed to assess whether these events are related to treatment.

UR - http://www.scopus.com/inward/record.url?scp=75749096035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749096035&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2009.09040576

DO - 10.1176/appi.ajp.2009.09040576

M3 - Article

VL - 167

SP - 190

EP - 197

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 2

ER -